Meeting
2020 ASCO Virtual Scientific Program
Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.
Authors
William Townsend
Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom
William Townsend , Christian Buske , Guillaume Cartron , David Cunningham , Martin J.S. Dyer , John G. Gribben , Zilu Zhang , Kaspar Rufibach , Tina Nielsen , Michael Herold , Wolfgang Hiddemann , Robert Marcus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT01332968
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8023)
DOI
10.1200/JCO.2020.38.15_suppl.8023
Abstract #
8023
Poster Bd #
356
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study.
First Author: Miguel Angel A. Canales Albendea
Poster
2020 ASCO Virtual Scientific Program
First-line immunochemotherapy for follicular lymphoma in the GALLIUM study: Prognostic value of PET-CT status after long-term follow-up.
First Author: Tina Nielsen
Poster
2022 ASCO Annual Meeting
Frontline treatment of follicular lymphoma with atezolizumab and obinutuzumab, with and without radiotherapy (The FLUORO study).
First Author: Eliza Anne Hawkes
Poster
2019 ASCO Annual Meeting
Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials.
First Author: Yucai Wang